Sepiapterin Fasting Dosing for Higher Plasma and Brain Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies using tetrahydrobiopterin (BH4) are limited by its inability to cross the blood-brain barrier effectively, while sepiapterin, a precursor to BH4, demonstrates greater membrane permeability but its plasma exposure is affected by food intake, leading to reduced therapeutic efficacy.
Innovation Solution
Administering sepiapterin without food increases its plasma, cerebrospinal fluid (CSF), and brain exposure by enhancing absorption rates and reducing peripheral conversion into BH4, thereby increasing CSF and brain penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If sepiapterin is administered with food, then absorption is slowed and peripheral conversion to BH4 is reduced, but plasma exposure and brain penetration are decreased
Solution Approach 1:
The patent applies periodic action by administering sepiapterin in a fasting state rather than continuously with food, creating distinct absorption phases that allow peak plasma concentrations to be achieved before peripheral conversion occurs. This temporal separation optimizes both absorption speed and overall exposure.
Solution Approach 2:
The patent changes the physiological parameter of gastric emptying and intestinal transit time by administering sepiapterin in a fasting state, which alters the absorption kinetics to achieve higher plasma exposure without excessive peripheral conversion to BH4.
2Quantity of substance
If sepiapterin is rapidly converted to BH4 in the periphery, then BH4 levels increase, but sepiapterin plasma exposure and brain penetration are reduced
Solution Approach 1:
The patent applies preliminary action by administering sepiapterin in a fasting state to establish high plasma concentrations before significant peripheral conversion occurs. This ensures that sepiapterin reaches the brain via passive diffusion before being converted to BH4 in peripheral tissues.
Solution Approach 2:
The patent applies the skipping principle by rapidly delivering sepiapterin to the brain before peripheral conversion can occur, exploiting the concentration gradient created by fasting-state administration to rush sepiapterin through the bloodstream to the central nervous system.
3Quantity of substance
If BH4 is administered directly, then BH4 levels increase, but ability to cross blood-brain barrier is insufficient
Solution Approach 1:
The patent uses sepiapterin as an intermediary compound that can cross the blood-brain barrier more effectively than BH4. Once inside the brain, sepiapterin is converted to BH4 by local enzymes, thereby overcoming the blood-brain barrier penetration limitation of direct BH4 administration.
Solution Approach 2:
The patent changes the chemical parameter by using sepiapterin instead of BH4, exploiting the different molecular properties of sepiapterin that allow for more efficient passive diffusion across the blood-brain barrier, while maintaining the ultimate goal of increasing brain BH4 levels through local conversion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in higher maximum concentrations and extended absorption of sepiapterin, enhancing therapeutic effects for BH4-related disorders by increasing monoamine metabolites like dopamine and serotonin in the brain.
Implementation Method 1
rapid gastrointestinal absorption
Implementation Method 2
saturation kinetics of liver cell membrane based active sepiapterin transporters
Implementation Method 3
saturation of intracellular sepiapterin reductase and/or dihydrofolate reductase enzymes responsible for reduction of sepiapterin into BH4
Implementation Method 4
reduction of sepiapterin into BH4
Implementation Method 5
increase in CSF and/or brain exposure with subsequent penetration of sepiapterin into brain cells
Data Source
AI summary
The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma. CSF, and/or brain exposure of sepiapterin.